A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

NCT06422884 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

213

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis
Progressive Fibrosing Interstitial Lung Disease

Interventions

DRUG: ENV-101
DRUG: Placebo

Sponsor

Endeavor Biomedicines, Inc.